Yo Max Amakusa
CEO
iBody Inc.
The startup develops a technology that facilitates the rapid identification and production of monoclonal antibodies from individual B cells, which are crucial for immune response. This approach enables patients to effectively stimulate and regulate their immune systems, addressing the need for targeted therapeutic interventions.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$1.4MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops a technology that facilitates the rapid identification and production of monoclonal antibodies from individual B cells, which are crucial for immune response. This approach enables patients to effectively stimulate and regulate their immune systems, addressing the need for targeted therapeutic interventions.